Cellanome is a developer of a multiomics platform that prusues increased clarity and resolution to help develop new therapies for complicated biological issues.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/04/2023 | Series B | $150MM | $xx.xx | $525.2MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
20,026,702
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
07/25/2022 | Series A-2 | $30.62MM | $xx.xx | $286.18MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,400,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
12/08/2021 | Series A | $21MM | $xx.xx | $198.71MM | Synetro Group | |
Price per Share
$xx.xx
Shares Outstanding
3,797,605
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Synetro Group
|
||||||
09/17/2021 | Series Seed | $2.62MM | $xx.xx | $32.96MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,245,616
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
09/17/2021 | Series Seed 2 | $2.05MM | $xx.xx | $32.96MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,737,280
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|